Merck's misconduct 'infected' patent litigation with Gilead: court by Eric Sagonowsky Friday, April 27, 2018 A Merck attorney who provided false testimony tainted the company's case, an appeals court ruled, and cost the company $200 million.
How will Gilead price CAR-T? Analysts expect $400,000+ by Eric Sagonowsky Tuesday, August 29, 2017 The Kite acquisition will likely position Gilead as a seller of superpricey medicine, where it could be vulnerable to shots from activists.
